Chicago, ILNCT07175051Now EnrollingIRB Ready

Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0) Clinical Trial in Chicago, IL

Access cutting-edge sickle cell anemia (hbss, or hbsβ-thalassemia0) treatment through this clinical trial at a research site in Chicago. Study-provided care at no cost to qualified participants.

Sponsored by University of Illinois at Chicago

Quick Self-Assessment

See if you qualify for this Chicago location

Preparing your pre-screening questions…

Expert Care in Chicago

Access sickle cell anemia (hbss, or hbsβ-thalassemia0) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related sickle cell anemia (hbss, or hbsβ-thalassemia0) treatment provided free

Apply for This Chicago Location

Check if you qualify for this sickle cell anemia (hbss, or hbsβ-thalassemia0) clinical trial in Chicago, IL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Chicago

    Convenient for IL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Chicago site if eligible
  4. 4Begin participation

About This Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0) Study in Chicago

Sickle cell anemia (SCA) is an inherited red blood disorder. The kidneys are among the most commonly affected organ systems in SCA. The Food and Drug Administration (FDA) has approved empagliflozin as a treatment to reduce the decline of kidney function in those with kidney disease. The proposed research study aims to determine whether empagliflozin can prevent the progression of kidney dysfunction in patients with sickle cell anemia (SCA) who are at high risk of developing advanced chronic kidney disease (CKD).

Sponsor: University of Illinois at Chicago

Who Can Participate

Inclusion Criteria

Documentation of SCA genotype (HbSS or HbSβ0-thalassemia)
Albuminuria defined by a UACR of 100 - 2,000 mg/g creatinine at the screening
Hemoglobin (Hb) ≥ 5.5 g/dL during screening
For participants taking Endari, the dose of Endari must be stable for at least one month prior to signing the ICF and with no anticipated need for dose adjustments during the study
For participants on crizanlizumab or chronic red blood cell transfusions, the therapy must have started at least 3 months prior to consent
For participants taking an angiotensin converting enzyme inhibitor (ACEi) or angiotensin II receptor blocker (ARB), the dose must be stable for at least 3 months prior to signing the ICF and with no anticipated need for dose adjustments during the study, in the opinion of the Investigator
Participants must demonstrate regular compliance with clinic visits and outpatient management
Participants, if female and of childbearing potential, will use highly effective methods of contraception from study start to 30 days after the last dose of the study drug
Participant has provided documented informed consent or assent

Exclusion Criteria

Concurrent diagnosis of diabetes mellitus
Female who is breast feeding, pregnant, or unwilling to use birth control as described in the protocol
Prior hypersensitivity or intolerance to a sodium-glucose cotransporter-2 inhibitor (SGLT2i)
Active or open leg ankle ulcer
Chronic urinary tract infection
Hospitalized for sickle cell crisis or other vaso-occlusive event within 14 days prior to signing consent
Hepatic dysfunction characterized by alanine aminotransferase (ALT) \>5× ULN
Participants with acute bacterial infection requiring antibiotic use should delay screening/enrollment until the course of antibiotic therapy has been completed
Participants with known active hepatitis A, B, or C or who are known to be human immunodeficiency virus (HIV) positive
Moderate to severe CKD (defined by an eGFR \< 30 mL/min/1.73m2, on chronic dialysis, or having received a kidney transplantation)
History of malignancy within the past 2 years prior to treatment Day 1 requiring chemotherapy and/or radiation (with the exception of local therapy for non-melanoma skin malignancy)
History of unstable or deteriorating cardiac or pulmonary disease within 6 months prior to consent including but not limited to the following:
Unstable angina pectoris or myocardial infarction or elective coronary intervention
Uncontrolled clinically significant arrhythmias
Any condition affecting drug absorption, such as major surgery involving the stomach (e.g. bariatric surgery) or small intestine (prior cholecystectomy is acceptable)
Participated in another clinical trial of an investigational agent (or medical device) within 30 days or 5 half-lives of agent, whichever is longer, or is currently participating in another trial of an investigational agent or medical device)
Medical, psychological, or behavioral conditions, which, in the opinion of the Investigator, may preclude safe participation, confound study interpretation, interfere with compliance, or preclude informed consent
Contraindication to MRI (certain pacemakers, electronic implants, shrapnel in the eyes, or certain intracranial aneurysm clips)

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Chicago?

Yes, this clinical trial (NCT07175051) has an active research site in Chicago, IL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0) Treatment Options in Chicago, IL

If you're searching for sickle cell anemia (hbss, or hbsβ-thalassemia0) treatment options in Chicago, IL, this clinical trial (NCT07175051) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Chicago research site is actively enrolling participants for this clinical trial. You'll receive care from experienced sickle cell anemia (hbss, or hbsβ-thalassemia0) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all sickle cell anemia (hbss, or hbsβ-thalassemia0) clinical trials near you to find additional studies recruiting in your area.

More Heart Attack Trials in Chicago, IL

See all heart attack clinical trials recruiting in Chicago — not just this study.

Browse Heart Attack Trials in Chicago →

Browse More Trials by Condition

Heart Attack TrialsAnkylosing Spondylitis TrialsInterstitial Cystitis TrialsAnemia TrialsSickle Cell Disease TrialsThalassemia TrialsMyocardial Infarction TrialsAll Conditions →

Ready to Join in Chicago?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Chicago, IL